Neurocrine CEO set to retire

Published on 29/05/2024 at 01:55

Reuters

-0.57%

May 28 (Reuters) - Neurocrine Biosciences said on Tuesday Kevin Gorman would retire as chief executive officer on Oct. 11 and will be succeeded by Kyle Gano. (Reporting by Sneha S K in Bengaluru; Editing by Maju Samuel)

Latest news about Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. Announces Results from New Analysis Using Real-World Data from CAHtalog	15/07	CI
Neurocrine Biosciences Leverages Picnichealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition	15/07	CI
Neurocrine Says New Analysis Shows Need for Congenital Adrenal Hyperplasia Therapies	15/07	MT
Wedbush Raises Price Target on Neurocrine Biosciences to $137 From $130, Keeps Outperform Rating	15/07	MT
Neurocrine Biosciences, Inc. Presents One-Year Data from Phase 3 CAHtalyst Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting	15/07	CI
Neurocrine Biosciences, Inc. Presents One-Year Data Showing Sustained Efficacy of CRENESSITY in Adult Patients, at ENDO 2025	14/07	CI
Neurocrine Biosciences Insider Sold Shares Worth $7,803,688, According to a Recent SEC Filing	12/07	MT
UBS Adjusts Price Target on Neurocrine Biosciences to $174 From $152, Maintains Buy Rating	09/07	MT
RBC Raises Price Target on Neurocrine Biosciences to $146 From $145, Keeps Outperform Rating	07/07	MT
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell Midcap Value Index	01/07	CI
Neurocrine Starts Phase 1 Trial of NBIP-01435 to Potentially Treat Congenital Adrenal Hyperplasia	01/07	MT
Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist	01/07	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 3000 Value Index	01/07	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 1000 Value-Defensive Index	30/06	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 2500 Value Index	30/06	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 1000 Value Index	30/06	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell Small Cap Comp Value Index	30/06	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 3000E Value Index	30/06	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell Midcap Value Benchmark	30/06	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 2500 Value Benchmark	30/06	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 3000 Value Benchmark	30/06	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell Small Cap Comp Value Benchmark	30/06	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 3000E Value Benchmark	30/06	CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 1000 Value Benchmark	30/06	CI
Neurocrine Biosciences, Inc. Presents New Post-Hoc Data Analyses from Kinect-Hd Study Demonstrating Significant Reduction in Disease Burden with Ingrezza®? (Valbenazine) Capsules for Huntington's Disease Chorea	28/06	CI